HIV enters the brain and doesn't leave, drugs intended to reduce brain inflammation increase virus levels
HIV can damage the brain and cause memory and cognitive problems. And once HIV enters the brain, it does not leave.
Jun 8, 2026
0
7
MeSH tree: D12.776.377.715.548.114
HIV can damage the brain and cause memory and cognitive problems. And once HIV enters the brain, it does not leave.
Jun 8, 2026
0
7
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of relapse in patients with IgG4-related disease, a rare chronic immune condition often misdiagnosed as ...
Jun 4, 2026
0
13
A consistent biological barrier that stops the immune system from making the antibodies most needed to protect the nose and throat from respiratory viruses has been identified. The discovery, led by researchers from the University ...
Jun 4, 2026
0
7
In the United States, children routinely receive an injectable form of the polio vaccine. This vaccine is very effective at preventing illness, but it doesn't block transmission of the polio virus as well as the oral polio ...
Jun 3, 2026
0
9
A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies. ...
Jun 2, 2026
0
7
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major ...
May 29, 2026
0
14
A Mount Sinai-led research team has demonstrated that autoimmunity, in which the body's immune system attacks its own tissues, is responsible for the often-debilitating and confounding symptoms of long COVID in a subset of ...
May 28, 2026
0
39
The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive ...
May 25, 2026
0
11
A Phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment. Researchers at Sylvester Comprehensive ...
May 21, 2026
0
5
The U.S. Food and Drug Administration's decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug had prolonged the lives of a third of ...
May 18, 2026
0
8